Document Detail

Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals.
MedLine Citation:
PMID:  11665796     Owner:  NLM     Status:  MEDLINE    
The time from admission to reperfusion in patients with acute myocardial infarction (AMI) was compared according to the type of hospital and treatment strategy. A total of 164 patients with a first AMI within 12h of onset were enrolled at one tertiary emergency center (TEC) and 6 community hospitals (CHs). The subjects were randomly assigned to receive either primary percutaneous transluminal coronary angioplasty (PTCA) (TEC-primary PTCA and CHs-primary PTCA groups) or 800,000 units of intravenous monteplase, half the standard dose of a mutant tissue plasminogen activator (t-PA), followed by rescue PTCA if the Thrombolysis in Myocardial Infarction (TIMI) flow grade was 2 or less (TEC-monteplase and CHs-monteplase groups) on the first coronary angiogram. Sixty minutes after admission, TIMI flow grade 3 rates of the study groups were as follows, in descending order: TEC-monteplase group, CHs-monteplase group, TEC-primary PTCA group, and CHs-primary PTCA group (56%, 41%, 36%, and 8%, respectively; p<0.01). However, there was no significant difference in the final TIMI flow grade 3 rate among the 4 groups. In the CHs, the peak creatine kinase tended to be lower in the monteplase group than in the primary PTCA group. The results suggest that low-dose monteplase followed by rescue PTCA is an effective strategy for promoting early reperfusion in patients with AMI, especially those who are treated at CHs.
K Kimura; K Tsukahara; T Usui; J Okuda; Y Kitamura; M Kosuge; T Sano; S Tohyama; O Yamanaka; Y Yoshii; S Umemura
Related Documents :
9129246 - Is the presence of hyperlipidemia associated with impairment of endothelium-dependent n...
11665796 - Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces ti...
15049386 - The relation between preprocedural c-reactive protein levels and early and late complic...
2947876 - Emergency coronary artery bypass for acute myocardial ischemia following percutaneous t...
6639816 - Echocardiographic features of tropical endomyocardial disease in south india.
10226856 - Cardiovascular pharmacology of the adenosine a1/a2-receptor agonist amp 579: coronary h...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Japanese circulation journal     Volume:  65     ISSN:  0047-1828     ISO Abbreviation:  Jpn. Circ. J.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-22     Completed Date:  2002-11-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7806868     Medline TA:  Jpn Circ J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  901-6     Citation Subset:  IM    
Division of Cardiology, Yokohama City University Medical Center, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary* / adverse effects,  standards
Clinical Protocols
Creatine Kinase / blood
Hospitals, Community / methods,  standards
Middle Aged
Myocardial Infarction / complications,  therapy*
Myocardial Reperfusion / adverse effects,  methods*,  standards
Thrombolytic Therapy
Time Factors
Tissue Plasminogen Activator / administration & dosage*
Reg. No./Substance:
EC Kinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery d...
Next Document:  Caspase-dependent and serine protease-dependent DNA fragmentation of myocytes in the ischemia-reperf...